Paper
0
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Authors
Margaret Phillips,Julie Lotharius
Kennan Marsh,John White,Anthony Dayan,Karen White,Jacqueline Njoroge,Farah Mazouni,Yanbin Lao,Sreekanth Kokkonda,D.R. Tomchick,Xiaoyi Deng,Trevor Laird,Sangeeta Bhatia,Sandra March,Caroline Ng,David Fidock,Sergio Wittlin,María Lafuente-Monasterio,Francisco Benito,Laura Alonso,María Martínez,Marı́a Jiménez-Dı́az,Santiago Ferrer,Íñigo Angulo‐Barturen,John Haselden,James Louttit,Yi Cui,Arun Sridhar,Anne‐Marie Zeeman,Clemens Kocken,Robert Sauerwein,Koen Dechering,Vicky Avery,Sandra Duffy,Michael Delves,Robert Sinden,Andrea Ruecker,Kristina Wickham,Rosemary Rochford,Janet Gahagen,Lalitha Iyer,Ed Riccio,Jon Mirsalis,Ian Bathhurst,Thomas Rueckle,Xavier Ding,Brice Campo,Didier Leroy,Michael Rogers,Pradipsinh Rathod,Jeremy Burrows,Susan Charman
+51 authors
,Alan ThomasPublished
Jul 15, 2015
Show more
Save
Tip0
TipSave
Abstract
The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.